BMC Medical Co., Ltd. (SHE:301367)
China · Delayed Price · Currency is CNY 46.64
+0.08 (0.17%)
At close: Sep 30, 2026
BMC Medical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,757 | 7,617 | 5,601 | 7,792 | 14,052 | - | |
Market Cap Growth | -21.86% | 36.00% | -28.12% | -44.55% | - | - |
Enterprise Value | 3,340 | 5,152 | 3,021 | 5,363 | 13,467 | - |
Last Close Price | 46.64 | 60.60 | 44.34 | 60.45 | 107.98 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 26.28 | 33.76 | 36.05 | 26.21 | 36.95 | - |
Forward PE | 20.15 | 27.93 | 23.74 | 16.44 | 29.83 | - |
PS Ratio | 4.18 | 6.57 | 6.64 | 6.94 | 9.93 | - |
PB Ratio | 1.87 | 2.50 | 1.97 | 2.80 | 5.37 | - |
P/TBV Ratio | 1.90 | 2.54 | 1.98 | 2.81 | 5.40 | - |
P/FCF Ratio | 43.19 | 77.77 | 40.54 | 61.36 | 39.98 | - |
P/OCF Ratio | 33.16 | 58.52 | 36.35 | 51.57 | 37.45 | - |
PEG Ratio | - | 1.56 | 1.56 | 2.06 | 0.44 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.42 | 4.44 | 3.58 | 4.78 | 9.52 | - |
EV/EBITDA Ratio | 11.33 | 21.95 | 27.58 | 19.54 | 33.35 | - |
EV/EBIT Ratio | 12.22 | 23.07 | 31.15 | 20.27 | 33.82 | - |
EV/FCF Ratio | 25.05 | 52.60 | 21.87 | 42.23 | 38.32 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.06 | 0.03 | 0.14 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.65 | 0.34 | 3.39 | 0.09 | 0.05 | 0.03 |
Debt / FCF Ratio | 1.45 | 0.86 | 2.92 | 0.21 | 0.06 | 0.04 |
Net Debt / Equity Ratio | -0.79 | -0.82 | -0.85 | -0.90 | -0.95 | -0.82 |
Net Debt / EBITDA Ratio | -8.52 | -10.66 | -21.98 | -9.10 | -6.18 | -2.61 |
Net Debt / FCF Ratio | -18.23 | -25.54 | -17.42 | -19.66 | -7.10 | -4.29 |
Asset Turnover | 0.39 | 0.34 | 0.27 | 0.38 | 0.80 | 1.22 |
Inventory Turnover | 4.01 | 5.10 | 4.08 | 3.86 | 5.17 | 4.59 |
Quick Ratio | 5.66 | 8.37 | 5.19 | 23.65 | 9.06 | 3.44 |
Current Ratio | 6.29 | 9.05 | 5.42 | 24.86 | 9.85 | 4.59 |
Return on Equity (ROE) | 7.58% | 7.86% | 5.64% | 11.10% | 24.52% | 33.66% |
Return on Assets (ROA) | 4.80% | 4.10% | 1.91% | 5.66% | 14.02% | 17.35% |
Return on Invested Capital (ROIC) | 37.09% | 40.66% | 24.22% | 115.02% | 334.52% | 225.63% |
Return on Capital Employed (ROCE) | 8.90% | 7.30% | 3.40% | 9.40% | 15.10% | 30.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.84% | 2.96% | 2.77% | 3.82% | 2.71% | - |
FCF Yield | 2.32% | 1.29% | 2.47% | 1.63% | 2.50% | - |
Dividend Yield | 1.01% | 0.78% | 0.64% | 0.84% | 0.95% | - |
Payout Ratio | 27.94% | 18.58% | 42.34% | 43.05% | - | 19.77% |
Buyback Yield / Dilution | -0.22% | 0.51% | 0.29% | -26.33% | -5.67% | 0.16% |
Total Shareholder Return | 0.79% | 1.29% | 0.94% | -25.49% | -4.72% | 0.16% |